BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-151@catalystbrief.girapphe.com
DTSTAMP:20261118T181554Z
LAST-MODIFIED:20261118T181554Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Readout: Sichuan Kelun-Biotech Biopharmaceutical Co.\, Ltd. — SKB
 264 [Apr 2027]
DESCRIPTION:Phase 3 primary completion: A Study of SKB264 Versus Investigat
 or's Choice Chemotherapy in Patients With Unresectable Recurrent or Metast
 atic Triple-Negative Breast Cancer.\nSource: https://clinicaltrials.gov/st
 udy/NCT06279364\nhttps://catalystbrief.girapphe.com/e/151?lang=en\nNot inv
 estment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/151?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
